| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6120270 | Journal of Clinical Virology | 2015 | 4 Pages |
Abstract
Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Ana Treviño, Teresa Cabezas, Ana Belén Lozano, Rosa GarcÃa-Delgado, Luis Force, José MarÃa Fernández-Montero, Carmen de Mendoza, Estrella Caballero, Vincent Soriano,